Abstract: Pure compound screening has previously identified the indolglyoxy lamidospermidine ascidian metabolites didemnidine A and B (2 and 3) to be weak growth inhibitors of Trypanosoma brucei rhodesiense (IC 50 59 and 44 μM, respectively) and Plasmodium falciparum (K1 dual drug resistant strain) (IC 50 41 and 15 μM, respectively), but lacking in selectivity (L6 rat myoblast, IC 50 24 μM and 25 μM, respectively). To expand the structure-activity relationship of this compound class towards both parasites, we have prepared and biologically tested a library of analogues that includes indoleglyoxyl and indoleacetic "capping acids", and polyamines including spermine (PA3-4-3) and extended analogues PA3-8-3 and PA3-12-3. 7-Methoxy substituted indoleglyoxylamides were typically found to exhibit the most potent antimalarial activity (IC 50 10-92 nM) but with varying degrees of selectivity versus the L6 rat myoblast cell line. A 6-methoxyindolglyoxylamide analogue was the most potent growth inhibitor of T. brucei (IC 50 0.18 μM) identified in the study: it, however, also exhibited poor selectivity (L6 IC 50 6.0 μM). There was no apparent correlation between antimalarial and anti-T. brucei activity in the series. In vivo evaluation of one analogue against Plasmodium berghei was undertaken, demonstrating a modest 20.9% reduction in parasitaemia.
Introduction
Alkyl amines belonging to the polyamine family [1] are widely distributed in nature, being isolated from a diverse range of terrestrial and marine sources. From the simple diamines putresine and cadaverine through to more complex examples of spermidine and spermine, polyamines have been reported to exhibit biological activities towards a large number of cellular targets and processes. While N-alkyl derivatives are generally cytotoxic or act synergistically with cytotoxins [2] [3] [4] , examples have been reported to act as potent epigenetic modulators [5] [6] [7] , to act as antioxidants [8] , and to exhibit anti-trypanosomal [9, 10] and anti-malarial properties [11] [12] [13] [14] [15] [16] .
As part of our own continuing search for new natural product leads for the development of treatments for neglected human diseases [17] [18] [19] [20] [21] , we recently reported the discovery of polyamine alkaloids orthidine F (1) [22, 23] and didemnidines A (2) and B (3) [24] as in vitro growth inhibitors of Plasmodium falciparum (K1 dual drug-resistant strain) ( Figure 1 ). In the case of orthidine F, the antimalarial potency of the natural product (IC 50 0.89 μM) [23] was increased substantially (IC 50 1.3 nM) by undertaking a structure-activity relationship study [25] , which also identified optimal structural attributes for antimalarial activity to be either a polyamine PA3-8-3 or PA3-12-3 [1] scaffold, and bearing 1, ω-disubstitution. Didemnidines A and B were found to be more modest growth inhibitors of both P. falciparum (IC 50 41 and 15 μM, respectively) and Trypanosoma brucei rhodesiense (IC 50 59 and 44 μM, respectively) [24] . Analogue 4, prepared during the synthesis of 3, was identified as the most active anti-protozoal compound in the limited series (Pf IC 50 8.4 μM, Tbr IC 50 9.9 μM), again suggesting that 1, ω-disubstitution of this alkaloid family might lead to the identification of more active examples. Herein we report the results of a structure-activity relationship study investigating the influence of indole substitution, the requirement for the side chain keto group and nature of the polyamine core to the observed anti-protozoal activity of didemnidines A and B. The library was evaluated for antimalarial activity against the NF54 drug sensitive strain of P. falciparum, for anti-trypanosomal activity against Trypanosoma brucei rhodesiense and for cytotoxicity towards the non-malignant L6 rat myoblast cell line. One analogue was also tested for in vivo antimalarial activity against Plasmodium berghei in mice.
Results and Discussion

Chemistry
Reaction of each of spermidine, spermine and di-tert-butyl octane-1,8-diylbis ((3-aminopropyl) carbamate) [25] with 2-(6-bromoindol-3-yl)glyoxylic acid [24] using PyBop as the coupling agent afforded, after chromatographic purification, analogues 5-7 in yields of 58%, 86% and 26%, respectively ( Figure 2 ). Subsequent removal of the Boc groups present in 7 with TFA in CH 2 Cl 2 gave tetraaminediamide 8 as the TFA salt. Previous studies by us have correlated electron-rich aryl substituents with enhanced anti-protozoal activity for 1, ω-disubstituted polyamines [23, 25] . To explore similar properties in the context of the didemnidines, we prepared 2-(1H-indol-3-yl)-2-oxoacetic acid (9) and the 5-, 6-and 7-methoxy analogues (10) (11) (12) (Figure 3 ) via a literature method [26] . Using each of 9-12, PyBop-mediated coupling with spermine, di-tert-butyl octane-1,8-diylbis((3-amino propyl)carbamate) [25] and di-tert-butyl dodecane-1,12-diylbis((3-aminopropyl)carbamate) [27, 28] , afforded analogues 13-24, while Boc group deprotection, again with TFA in CH 2 Cl 2 , gave tetraamine diamides 25-32 as their corresponding di-TFA salts ( Figure 4 ). We finally sought to explore the influence of the sidechain keto group on the observed activity of the didemnidines. Thus PyBOP or HATU-mediated coupling of commercially available indole-3-acetic acid with di-tert-butyl butane-1,4-diylbis((3-aminopropyl)carbamate) [25, 27] , di-tert-butyl octane-1,8-diylbis((3-aminopropyl)carbamate) [25] and di-tert-butyl dodecane-1, 12-diylbis ((3-aminopropyl)carbamate) [27, 28] afforded polyamine amides 33-35 with yields of 39%, 35% and 44%, respectively ( Figure 5 ). Subsequent removal of the Boc groups with TFA in CH 2 Cl 2 gave tetraamine diamides 36-38 as TFA salts. 
Biological Activities
In Vitro Biological Evaluation
The library of target analogues were screened against the protozoa T. brucei rhodesiense and P. falciparum and for cytotoxicity towards the rat skeletal myoblast cell line L6 and the results are summarized in Table 1 . Bromoindoles 5-8 (entries 4-7) were all more active against Pf than the original natural products 2 and 3 and analogue 4. Only one analogue however, bis-tert-carboxylcarbonyl protected 7, demonstrated some degree of selectivity with L6 cytotoxicity of IC 50 92 μM and a selectivity index of 340 (entry 6). Of spermine analogues 13-16 (entries 8-11), debromoindole 13 (entry 8) exhibited good potency towards Pf (IC 50 0.12 μM) with improved selectivity (L6 IC 50 60 μM, Pf SI 500). All of the tert-butoxycarbonyl protected PA3-8-3 analogues tested (18-20, entries 12-14) exhibited acceptable levels of selectivity, with 7-methoxyindole 20 (entry 14) identified as being a potent growth inhibitor of Pf (IC 50 92 nM) with excellent selectivity (L6 IC 50 ≥ 120 μM, Pf SI ≥ 1300). The corresponding Boc-protected PA3-12-3 analogues 21-24 (entries 15-18) were less active towards Pf and only modestly selective. Removal of the Boc group afforded 25-32 (entries [19] [20] [21] [22] [23] [24] [25] [26] , of which PA3-12-3 analogues 29 (entry 23) and 32 (entry 26) were identified as potent anti-Pf compounds but with only moderate selectivity (Pf SI 70 and 210, respectively). Using the rather crude tool of averaging anti-Pf IC 50 values for all PA3-8-3 and PA3-12-3 analogues indicates that those that contain the PA3-8-3 core are typically 6-7 times more active (average IC 50 0.13 μM) than the corresponding PA3-12-3 analogues (average IC 50 0.89 μM). Examination of the anti-Pf data observed for the set of indole-3-acetic acid analogues 33-38 (entries 27-32) suggested little influence of the keto group in the sidechain for potency, but that the analogues were typically of similar or more potent cytotoxicity. Compared to our previous studies of antimalarial benzamide, phenylacetamide, phenethylamide and phenyl-3-propanamide polyamine analogues [23, 25] , the present results indicate indoleglyoxyl and indoleacetamides to be more cytotoxic and less potent against Pf, suggesting future studies should be directed towards the former classes of "capping acids".
In the case of anti-Trypanosoma brucei rhodesiense activity, PA3-12-3 analogues 29-32 (entries [23] [24] [25] [26] were the most active (IC 50 0.18-0.27 μM), but unfortunately were also some of the more cytotoxic diamides prepared.
In Vivo Anti-Malarial Evaluation
Analogue 20 was selected for in vivo evaluation in Plasmodium berghei infected mice. Using a standard test protocol [30] , a repeated ip dose of 50 (mg/kg)/day for four days led to a 20.9% reduction in parasitaemia. No increase in mean survival time was observed.
Experimental Section
General
HRMS data were acquired on a Bruker micrOTOF-QII mass spectrometer (Bruker Daltonik GmbH, Bremen, Germany). Infrared spectra were recorded on a Perkin-Elmer Spectrum 100 Fourier-transform IR spectrometer (Perkin Elmer, Waltham, MA,) equipped with a universal ATR accessory. Melting points were obtained on an Electrothermal melting point apparatus and are uncorrected. NMR spectra were recorded using either a Bruker Avance DRX 300 or 400 spectrometer (Bruker BioSpin GmbH, Rheinstetten, Germany) operating at 300 MHz or 400 MHz for 1 H nuclei and 75 MHz or 100 MHz for 13 [26] , 2-(6-bromo-1H-indol-3-yl)-2-oxoacetic acid [24] , di-tert-butyl butane-1,4-diylbis((3-aminopropyl)carbamate) [25, 27] , di-tert-butyl octane-1, 8-diylbis((3-aminopropyl)carbamate) [25] and di-tert-butyl dodecane-1,12-diylbis((3-aminopropyl) carbamate) [27, 28] have been reported previously.
Synthetic Procedures
General Procedure A: Amide Bond Formation
To a solution of carboxylic acid (2.05 equiv.), diamine (1 equiv.), and PyBOP (2.05 equiv.) in DMF (1 mL) was added Et 3 N (3 equiv.). The reaction mixture was allowed to stir under N 2 at room temperature for 23 h. The solution was dried in vacuo and the crude reaction product purified by C 8 reversed-phase column chromatography (20%-30% MeOH/H 2 O (+0.05%TFA)) to afford the target diamide as the bis-trifluoroacetate salt or by silica gel column chromatography (0%-1% MeOH in CH 2 Cl 2 ) to afford the target diamide as the free base.
General Procedure B: Removal of Boc Protecting Group
A solution of tert-butyl-carbamate derivative in CH 2 Cl 2 (2 mL) and TFA (0.2 mL) was stirred at room temperature under N 2 for 2 h, then dried in vacuo to afford the deprotected analogue. In some cases the product required no further purification, while in other cases, purification was achieved by C 18 reversed-phase column chromatography eluting with 0%-50% MeOH/H 2 O (+0.05% TFA).
Using general procedure A, 2-(6-bromo-1H-indol-3-yl)-2-oxoacetic acid [24] 
Using general procedure A, 2-(6-bromo-1H-indol-3-yl)-2-oxoacetic acid [24] (0.12 g, 0.42 mmol), di-tert-butyl octane-1,8-diylbis((3-aminopropyl)carbamate) [25] 3.2.6.
Using general procedure B, reaction of 7 (9 mg, 9.4 μmol) in CH 2 Cl 2 (1.7 mL) with TFA (0.3 mL) afforded 8 as a yellow gum (9 mg, quant. yield) which required no further purification.
R f = 0. 
2-(5-Methoxy-1H-indol-3-yl)-2-oxoacetic Acid (10)
The target compound 10 was prepared using a previously published method [26] . To a solution of 5-methoxyindole (0.15 g, 0.985 mmol) in anhydrous diethyl ether (18 mL) was added oxalyl chloride (0.13 mL, 1.48 mmol) dropwise at 0 °C. Reaction was stirred at 0 °C for 2 h, during which time an orange precipitate was formed. Saturated aq. NaHCO 3 (6 mL) was added, and the reaction mixture heated at reflux for 2 h. After cooling to r.t., 10% HCl was added to adjust the solution to pH 1, the resulting precipitate filtered and dried under vacuum to yield 10 as an orange powder (0.20 g, 91% yield).
Mp 
2-(6-Methoxy-1H-indol-3-yl)-2-oxoacetic Acid (11)
The target compound 11 was prepared using a previously published method [26] . To a solution of 6-methoxyindole (0.13 g, 0.866 mmol) in anhydrous diethyl ether (10 mL) was added oxalyl chloride (0.11 mL, 1.30 mmol) dropwise at 0 °C. The reaction mixture was allowed to stir at 0 °C for 3 h before it was warmed to r.t. Saturated aq. NaHCO 3 (10 mL) was then added, and the reaction mixture heated at reflux for 1 h. After cooling to r.t., the pH of the reaction mixture was adjusted to 1 using 10% HCl. The resulting green precipitate was filtered, washed with cold diethyl ether (30 mL) and dried under vacuum to yield 11 as a green powder (0.18 g, 97% yield) which was used in the next step without further purification.
Mp 3.2.9. 2-(7-Methoxy-1H-indol-3-yl)-2-oxoacetic Acid (12) The target compound 12 was prepared using a previously published method [26] . To a solution of 7-methoxyindole (0.30 g, 2.04 mmol) in anhydrous diethyl ether (9 mL) was added oxalyl chloride (0.52 mL, 6.11 mmol) dropwise at 0 °C. The reaction mixture was stirred at 0 °C for 1.5 h, followed by dropwise addition of saturated aq. NaHCO 3 (10 mL), and then heated at reflux for 20.5 h. After cooling to r.t., 10% HCl was added to the reaction mixture to adjust pH to 1 and the resulting brown precipitate was filtered, washed with cold diethyl ether (20 mL), and dried under vacuum to yield 12 as a brown solid (0.45 g, quant. yield) which was used in the next step without further purification.
Mp 3.2.10.
Using general procedure A, 2-(1H-indol-3-yl)-2-oxoacetic acid (9) Using general procedure A, 2-(5-methoxy-1H-indol-3-yl)-2-oxoacetic acid (10) Using general procedure A, 2-(1H-indol-3-yl)-2-oxoacetic acid (9) (109 mg, 0.58 mmol), di-tert-butyl octane-1,8-diylbis((3-aminopropyl)carbamate) [25] (120 mg, 0.26 mmol), PyBOP (300 mg, 0.58 mmol) and Et 3 N (218 μL, 1.5 mmol) afforded 17 as a white gum (34 mg, 16% yield).
R 
Di-tert-butyl Octane-1,8-diylbis((3-(2-(6-methoxy-1H-indol-3-yl)-2-oxoacetamido) propyl)carbamate) (19)
Using general procedure A, 2-(6-methoxy-1H-indol-3-yl)-2-oxoacetic acid (11) (94 mg, 0.43 mmol), di-tert-butyl octane-1,8-diylbis((3-aminopropyl)carbamate) [25] 
Di-tert-butyl Octane-1,8-diylbis((3-(2-(7-methoxy-1H-indol-3-yl)-2-oxoacetamido)propyl) carbamate) (20)
Using general procedure A, 2-(7-methoxy-1H-indol-3-yl)-2-oxoacetic acid (12) (86 mg, 0.39 mmol), di-tert-butyl octane-1,8-diylbis((3-aminopropyl)carbamate) [25] 
Di-tert-butyl Dodecane-1,12-diylbis((3-(2-(1H-indol-3-yl)-2-oxoacetamido)propyl) carbamate) (21)
Using general procedure A, 2-(1H-indol-3-yl)-2-oxoacetic acid (9) (19 mg, 0.10 mmol), di-tert-butyl dodecane-1,12-diylbis((3-aminopropyl)carbamate) [27, 28] 
Di-tert-butyl Dodecane-1,12-diylbis((3-(2-(5-methoxy-1H-indol-3-yl)-2-oxoacetamido) propyl)carbamate) (22)
Using general procedure A, 2-(5-methoxy-1H-indol-3-yl)-2-oxoacetic acid (10) (50 mg, 0.23 mmol), di-tert-butyl dodecane-1,12-diylbis((3-aminopropyl)carbamate) [27, 28] 
Di-tert-butyl Dodecane-1,12-diylbis((3-(2-(7-methoxy-1H-indol-3-yl)-2-oxoacetamido) propyl)carbamate) (24)
Using general procedure A, 2-(7-methoxy-1H-indol-3-yl)-2-oxoacetic acid (12) (45 mg, 0.21 mmol), di-tert-butyl dodecane-1,12-diylbis((3-aminopropyl)carbamate) [27, 28] Using general procedure B, reaction of 22 (11 mg, 12 μmol) in CH 2 Cl 2 (1.8 mL) with TFA (0.2 mL) afforded 30 as a yellow gum (8 mg, 90% yield) which required no further purification.
R Using general procedure A, 2-(1H-indol-3-yl)acetic acid [26] (40 mg, 0.23 mmol), di-tert-butyl butane-1,4-diylbis((3-aminopropyl)carbamate) [25, 27] To a stirred solution of 2-(1H-indol-3-yl)acetic acid [26] (51 mg, 0.29 mmol), DIPEA (68 μL, 0.41 mmol) in DMF (1 mL) was added HATU (110 mg, 0.29 mmol). The reaction mixture was stirred under N 2 at r.t. for 80 min, followed by the addition of di-tert-butyl octane-1,8-diylbis ((3-aminopropyl)carbamate) [25] (63 mg, 0.14 mmol). The reaction mixture was further stirred for 22 h and then partitioned between H 2 O (30 mL) and CH 2 Cl 2 (3 × 40 mL). The combined organic extracts were washed with brine (20 mL) and dried over MgSO 4 Using general procedure B, reaction of 35 (10 mg, 12 μmol) in CH 2 Cl 2 (1.7 mL) with TFA (0.3 mL) followed by purification using LH20 column chromatography to afford 38 as a pink oil (8 mg, 92% yield). 
Biological Assays
In Vitro Anti-Protozoal Activity
The in vitro activities against the protozoan parasites T.b. rhodesiense, and P. falciparum and cytotoxicity assessment against L6 cells were determined as reported elsewhere [29] . The following strains, parasite forms and positive controls were used: T.b. rhodesiense, STIB900, trypomastigote forms, melarsoprol, IC 50 of 0.005 μM; P. falciparum, NF54, erythrocytic stages, chloroquine, IC 50 of 0.004 μM and L6 cells, rat skeletal myoblasts, podophyllotoxin, IC 50 of 0.019 μM.
In Vivo Anti-Malarial Efficacy Studies
In vivo anti-malarial activity was assessed as previously described [30] . Groups of three female NMRI mice (20-22 g ) were intravenously infected with 2 × 10 7 parasitized erythrocytes on day 0 with GFP-transfected P. berghei strain ANKA [32] . Compounds were formulated in 100% DMSO, diluted 10-fold in distilled water and administered intraperitoneally in a volume of 10 mL· kg −1 on four consecutive days (4, 24, 48 and 72 h post infection). Parasitemia was determined on day 4 post infection (24 h after last treatment) by FACS analysis. Activity was calculated as the difference between the mean per cent parasitaemia for the control (n = 5 mice) and treated groups expressed as a per cent relative to the control group. The survival of the animals was usually monitored up to 30 days: a compound was considered curative if the animal survived to day 30 after infection with no detectable parasites. In vivo efficacy studies in mice were conducted according to the rules and regulations for the protection of animal rights ("Tierschutzverordnung") of the Swiss "Bundesamt für Veterinä rwesen". They were approved by the veterinary office of Canton Basel-Stadt, Switzerland.
Conclusions
The polyamine marine natural products didemnidine A (2) and B (3) have been previously identified as weak in vitro growth inhibitors of Trypanosoma brucei rhodesiense and Plasmodium falciparum. A series of 1, ω-substituted polyamine analogues were prepared that explored the influence of "capping acids" indole-3-glyoxylic acid and indole-3-acetic acid, length of polyamine chain and the presence or absence of mid-chain nitrogen substitution on antiprotozoal activity. Three analogues, one containing a PA3-8-3 core (20) and two containing PA3-12-3 cores (29, 32) were identified as particularly potent antimalarials, with the former example also exhibiting good selectivity. Several analogues were identified that exhibit more enhanced anti-Trypanosoma brucei activity than the original natural product hits, but these same analogues also exhibited cytotoxicity, making them poorly selective. PA3-8-3 analogue 20 was only mildly active against P. berghei infection in a mouse model.
